MCCC

MCCC is a biotechnology company focused on developing novel therapeutic interventions for rare metabolic disorders, specifically targeting deficiencies in the methylcrotonyl-CoA carboxylase enzyme. The company's primary research efforts are directed toward small molecule stabilizers and enzyme replacement strategies to address methylcrotonylglycinuria. By leveraging advanced biochemical screening and structural biology, MCCC aims to provide disease-modifying treatments for patients with limited options. The company is currently in the pre-clinical stage, advancing its lead candidates through optimization and safety profiling.